Monte Rosa Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Markus Warmuth
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 645 Summer Street Boston MA United States of America 02210
- IPO Date
- Jun 24, 2021
- CIK
- 0001826457
- Website
- monterosatx.com
- Similar Companies
- Business
- Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company primarily engaged in the discovery and development of novel therapeutics to address rare diseases and immuno-oncology conditions. The company specializes in producing small molecule drug candidates that target molecular pathways involved in immune regulation and inflammatory diseases. Key product categories include precision immunotherapies, with a platform leveraging translational biology, chemistry, and clinical expertise to identify and advance therapies modulating immune responses. Monte Rosa Therapeutics focuses on developing treatments for patients with serious medical conditions with unmet needs. Headquartered in Dallas, Texas, and founded recently, the company operates within the biotechnology and pharmaceutical industry, serving global markets through clinical development programs. Monte Rosa Therapeutics targets investors, clinicians, and researchers interested in innovative treatments for immune-related diseases and rare disorders. The latest major company changes include strategic partnerships with leading research institutions and pharmaceutical companies to accelerate drug discovery and development. Monte Rosa Therapeutics has recently expanded its pipeline through novel product launches and entered collaborations to enhance clinical trial capabilities. The company has not announced any recent name changes or reorganization but has positioned itself for growth by broadening therapeutic focuses and strengthening its scientific and operational platform within the last 1-2 years. These efforts emphasize Monte Rosa Therapeutics' commitment to advancing precision medicines from discovery through clinical development to commercialization.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants